Spots Global Cancer Trial Database for her2+ breast cancer
Every month we try and update this database with for her2+ breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | NCT04102618 | Breast Cancer | Pelareorep Letrozole Atezolizumab Trastuzumab | 18 Years - | Oncolytics Biotech | |
| Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | NCT05180006 | Breast Cancer | Atezolizumab In... Bevacizumab Pertuzumab Trastuzumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | NCT02229149 | Breast Neoplasm... Malignant Tumor... | Trastuzumab Pertuzumab Vinorelbine, Pa... | 18 Years - | US Oncology Research | |
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | NCT05132582 | HER2 Positive B... | Tucatinib Trastuzumab Pertuzumab Combination pro... Placebo | 18 Years - | Seagen Inc. | |
| A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease | NCT00679341 | Breast Cancer | Trastuzumab emt... Trastuzumab Docetaxel | 18 Years - | Hoffmann-La Roche | |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | NCT04296942 | Breast Cancer Triple Negative... HER2+ Breast Ca... Hormone Recepto... Metastatic Brea... | Brachyury-TRICO... Entinostat M7824 Ado-trastuzumab... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | NCT03632941 | Breast Cancer HER2+ Breast Ca... | VRP-HER2 Pembrolizumab | 18 Years - | Duke University | |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | NCT05534438 | Oligometastatic... Breast Cancer Metastatic Brea... Metastatic Brea... ER+ Breast Canc... HER2+ Breast Ca... | Stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer | NCT02229149 | Breast Neoplasm... Malignant Tumor... | Trastuzumab Pertuzumab Vinorelbine, Pa... | 18 Years - | US Oncology Research | |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | NCT04296942 | Breast Cancer Triple Negative... HER2+ Breast Ca... Hormone Recepto... Metastatic Brea... | Brachyury-TRICO... Entinostat M7824 Ado-trastuzumab... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer | NCT04900311 | HER2+ Early or ... | pyrotinib + tra... pertuzumab + tr... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy | NCT00928330 | Metastatic Brea... | GDC-0941 Trastuzumab trastuzumab-MCC... | 18 Years - | Genentech, Inc. | |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | NCT04539938 | HER2 Positive B... | tucatinib trastuzumab der... | 18 Years - | Seagen Inc. | |
| Pyrotinib Versus Pertuzumab in Combination With Neoadjuvant Trastuzumab and Nab-Paclitaxel in HER2+ Early or Locally Advanced Breast Cancer | NCT04900311 | HER2+ Early or ... | pyrotinib + tra... pertuzumab + tr... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | NCT05534438 | Oligometastatic... Breast Cancer Metastatic Brea... Metastatic Brea... ER+ Breast Canc... HER2+ Breast Ca... | Stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer | NCT06172127 | HER2-positive B... | Trastuzumab der... Phesgo 1,200 MG... Phesgo 600 MG /... | 18 Years - | MedSIR | |
| A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer | NCT04539938 | HER2 Positive B... | tucatinib trastuzumab der... | 18 Years - | Seagen Inc. | |
| Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | NCT05180006 | Breast Cancer | Atezolizumab In... Bevacizumab Pertuzumab Trastuzumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review | NCT05931042 | HER2+ Breast Ca... | Trastuzumab | 18 Years - | Rawalpindi Medical College | |
| A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer | NCT05534438 | Oligometastatic... Breast Cancer Metastatic Brea... Metastatic Brea... ER+ Breast Canc... HER2+ Breast Ca... | Stereotactic bo... | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
